All In Biotech

Drug Trial Radar · NCT05091242

The PREVENT AGITATION Trial II - Children ≤1 Year

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

336

Planned (sponsor's estimate)

Start

Oct 25, 2021

Primary completion

Jan 31, 2028

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 3 months, up to 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Emergence agitation is a clinical condition in which the child experiences a variety of behavioural disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. Emergence agitation is a common challenge in children with a reported incidence of approximately 25% ranging from 10 to 80 %. Clonidine is often used off-label in paediatric anaesthesia e.g. sedation in the intensive care unit, prevention of withdrawal symptoms after long-term sedation, as premedication before induction of anaesthesia or as treatment/prevention of emergence agitation. The study is designed as a randomised, placebo-controlled clinical trial evaluating efficacy and safety of a single dose of intraoperative clonidine in children 3-12 months, including pharmacokinetics.

Conditions

  • Emergence Delirium

Interventions

  • ClonidineDrug

    Clonidine injection 3 mcg/kg once

  • Sodium chlorideDrug

    Sodium chloride 0.9 % injection 0.2 mL/kg once

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of emergence agitation during stay in postanaesthetic care unit (PACU)Time frame: From admission to PACU to discharge from PACU, up to app. 4 hours. Emergence agitation is considered present ("Yes"), if Watcha score>2 at ANY time point within the given time frame.
  2. Compartmental clearance for pharmacokinetic profiling.Time frame: Samples will be collected at baseline and at 5, 15, 30, and 60 minutes post dosage and just prior prior to removal of iv-access ie., at latest 120-240 min post dosage.
  3. Volume of distribution for pharmacokinetic profiling.Time frame: Samples will be collected at baseline and at 5, 15, 30, and 60 minutes post dosage and just prior prior to removal of iv-access ie., at latest 120-240 min post dosage.
  4. T1/2 for pharmacokinetic profiling.Time frame: Samples will be collected at baseline and at 5, 15, 30, and 60 minutes post dosage and just prior prior to removal of iv-access ie., at latest 120-240 min post dosage.

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Perth Children's Hospital, Department of Anaesthesia and Pain Medicine

    Perth, Nedlands, Australia · Recruiting

  • Copenhagen University Hospital, Rigshospitalet

    Copenhagen, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.